- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
CVD catheter cleared for new uses
The Food and Drug Administration has given Endosonics subsidiaryCardiovascular Dynamics (CVD) clearance to market expanded applicationsfor its Periflow line of peripheral balloon angioplasty-infusioncatheters. Earlier this year, the FDA cleared Periflow
The Food and Drug Administration has given Endosonics subsidiaryCardiovascular Dynamics (CVD) clearance to market expanded applicationsfor its Periflow line of peripheral balloon angioplasty-infusioncatheters. Earlier this year, the FDA cleared Periflow for percutaneoustransluminal angioplasty (PTA) as well as the infusion of site-specificcontrast media for peripheral vascular anatomy (SCAN 2/15/95).The agency's most recent action allows Periflow to be marketedfor both PTA and the site-specific delivery of therapeutic pharmaceuticalsinto the peripheral vasculature. CVD, of Irvine, CA, plans tobegin U.S. shipments of Periflow by the end of this year.
In other news, Endosonics said CVD has received approval fromthe Japanese Ministry of Health to market its Controlled AngioplastyTechnology catheters in Japan.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
